Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Diagnostic Tool on Horizon for Surgeons Treating Cancer Patients

By LabMedica International staff writers
Posted on 05 Jul 2015
Researchers have successfully developed a new tool that may enable surgeons to determine if a biopsy tissue is cancerous while their patients are still on the operating table, without routinely requiring microscope-based pathology analysis of the tissue. More...


The tool, developed by a team of researchers from the Department of Energy (DOE)'s Oak Ridge National Laboratory (ORNL; Oak Ridge, TN, USA) and the Harvard Medical School teaching hospital Brigham & Women’s Hospital (Boston, MA, USA), is a new mass spectrometry (MS)-based technology—an automated droplet-based surface-sampling probe that accomplishes in about 10 minutes what currently takes 20–30 minutes. First author Dr. Vilmos Kertesz of ORNL expects the time to soon be further cut to 5 minutes.

The system has been successfully used for spatially resolved sampling and detection of drugs and metabolites from thin sections of animal tissue as well as of proteins from dried blood. For the proof-of-concept study, the researchers rapidly profiled two hormones from human pituitary tissue.

“Instead of having to cut and mount tissue and wait for a trained pathologist to review the sample under a microscope, a technician might soon perform an equally conclusive test in the operating environment,” said Dr. Kertesz. The technology may also become an attractive alternative to the traditional diagnostic method of biomarker testing with immunohistochemistry (IHC). Although IHC provides a high degree of spatial recognition, it is time consuming and is limited by the quality and specificity of the antibody.

The success of this work can be traced back to patents resulting from previous DOE projects and it advances the liquid microjunction surface sampling probe technology first patented by ORNL. Currently ORNL houses the only laboratories worldwide that have this automated droplet-based surface sampling probe and the requisite software.

While other MS-based techniques (such as desorption electrospray ionization and rapid evaporative ionization) are being evaluated for classifying tumors and providing prognostic information, they are limited mainly to analysis of lower molecular weight biomolecules. The new droplet-based method overcomes this limitation. “The ability to quickly characterize the tissue distribution of larger macromolecular biomarkers like peptides and proteins would harness the diagnostic value of validated IHC approaches for surgical decision-making,” said Dr. Kertesz, “On the basis of the results and the relative simplicity, rapidity, and specificity of our method, there is great potential for our technology to assist surgeons in the detection of cancer from tissue biopsy samples.”

The study, Kertesz V et al., was published June 18, 2015, in the journal Analytical and Bioanalytical Chemistry.

Related Links:

Oak Ridge National Laboratory
Brigham & Women’s Hospital 



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.